CTIC

Pacritinib | PRE-VENT

COVID-19

Stage (next event)

Expected Date

Phase 3 (Top-line Data)

Q4 2020

Catalyst Info & Data Links

TITLE: Pacritinib for COVID-19 - Top-line Data

  • ClinicalTrial.gov (NCT04404361): PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer


WHAT IS THE NEXT CATALYST EVENT?

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity (learn more - National Cancer Institute)

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon